Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

7 Dec 2006 07:02

ReNeuron Group plc07 December 2006 Director Share Purchases Guildford, UK, 6 December 2006: ReNeuron Group plc (LSE: RENE) today announcesthe following purchases of ordinary shares in ReNeuron by directors of theCompany at 19.5p per share. Name Number of Shares Purchased Michael Hunt 51500John Sinden 36000Mark Docherty 51400(1)Trevor Jones 25700Paul Harper 57500 Following these purchases the directors of ReNeuron have the following interestsin issued ordinary shares in ReNeuron: Name Number of shares Percentage of issued share capitalMichael Hunt 174,613 0.18%John Sinden 1,219,925(2) 1.22%Mark Docherty 146,400(3) 0.15%Trevor Jones 83,200 0.08%Paul Harper 83,200 0.08% The current issued ordinary share capital of the Company is 99,604,700 shares. (1) = including 24,700 ordinary shares acquired by the MD FURBS, a funded unapproved retirement benefit scheme established by Mark Docherty (2) = in addition John Sinden holds 117,160 ordinary shares on trust for family members (3) = including 120,700 ordinary shares held by the MD FURBS, a funded unapproved retirement benefit scheme established by Mark Docherty ENDS Enquiries: ReNeuronMichael Hunt, CEO Tel: 44 (0)1483 302 560John Sinden, CSO Financial DynamicsDavid Yates Tel: 44 (0)20 7831 3113Nicola Daley This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Dec 20227:06 amRNSPositive iPSC data presented at conference
2nd Dec 20224:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20224:35 pmRNSPrice Monitoring Extension
2nd Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSInterim Results
7th Oct 20227:00 amRNSPositive Exosome data presented at US conference
22nd Sep 20227:00 amRNSReNeuron to present new data at Exosome conference
14th Sep 20227:00 amRNSDirectorate and Executive Changes
9th Sep 202210:58 amRNSResult of AGM
2nd Sep 202211:01 amRNSDirector/PDMR Shareholding
1st Sep 20227:00 amRNSBlock Listing Review and Total Voting Rights
15th Aug 20223:25 pmRNSPosting of AR & Accounts & Notice of AGM
1st Aug 20227:00 amRNSDirectorate Change
15th Jul 20227:00 amRNSGrant of Options
14th Jul 20227:00 amRNSShare Purchase by a Director
13th Jul 20227:00 amRNSShare Purchase by a Director
4th Jul 20227:00 amRNSPreliminary Results
1st Jul 20227:00 amRNSFosun Tech Transfer and Supply Agreement update
20th Jun 20227:00 amRNSNotice of Results
3rd May 20227:00 amRNSReNeuron to present at ISCT 2022 in San Francisco
25th Apr 20227:00 amRNSDirector Declaration
23rd Mar 20227:00 amRNSHolding(s) in Company
22nd Mar 20227:01 amRNSDirectorate Changes
22nd Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
8th Mar 20227:00 amRNSBlock Listing Review and Total Voting Rights
7th Mar 20224:00 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSDirector exit arrangements
11th Feb 20224:41 pmRNSSecond Price Monitoring Extn
11th Feb 20224:36 pmRNSPrice Monitoring Extension
11th Feb 20222:38 pmRNSHolding(s) in Company
11th Feb 20227:00 amRNSDirector Change
10th Feb 20229:49 amRNSHolding(s) in Company
9th Feb 202211:59 amRNSHolding(s) in Company
4th Feb 20225:17 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSInvestor Presentation
26th Jan 20222:06 pmRNSSecond Price Monitoring Extn
26th Jan 20222:01 pmRNSPrice Monitoring Extension
18th Jan 20224:35 pmRNSPrice Monitoring Extension
18th Jan 20222:06 pmRNSSecond Price Monitoring Extn
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:05 amRNSSecond Price Monitoring Extn
18th Jan 202211:00 amRNSPrice Monitoring Extension
18th Jan 20229:05 amRNSSecond Price Monitoring Extn
18th Jan 20229:00 amRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSStrategic update
13th Jan 20227:00 amRNSAdditional agreement with Fosun Pharma for CTX
11th Jan 20227:00 amRNSNew Senior Appointment
17th Dec 20212:00 pmRNSDirector Declaration
30th Nov 20217:00 amRNSInterim Results
19th Nov 20217:00 amRNSCTX-iPSC platform data shows commerical potential

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.